10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Cerevance, a UK-based clinical-stage biopharmaceutical company advancing new medicines for brain diseases, has formed a multi-year research alliance with Japan’s Takeda Pharmaceutical to identify novel target proteins expressed in the central nervous system and to develop new therapies against them for certain gastrointestinal (GI) disorders. 18 December 2019
In a surprise move, Ipsen chief executive David Meek has quit his position at the French drugmaker to take the helm at a small gene therapy startup, FerGene. 18 December 2019
The US Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) voted by a narrow margin of 7 to 5 in favor of recommending Lynparza (olaparib) as a first-line maintenance monotherapy for patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas, whose disease has not progressed following 1st-line platinum-based chemotherapy 18 December 2019
US biotech Alnylam Pharmaceuticals cemented its standing as the leading RNAi therapeutics company on Tuesday by presenting positive Phase III data on its latest candidate. 17 December 2019
USA-based genetics medicines developer Wave Life Sciences saw its shares crash more than 55% to $26.79 by close of trading Monday, after announcing the discontinuation of two trials in Duchenne muscular dystrophy (DMD). 17 December 2019
Following Monday morning’s notice of clearance from the UK’s Competition and Markets Authority, later the same day the USA’s Federal Trade Commission revealed closure of its investigation into Swiss pharma giant Roche’s proposed $4.3 billion acquisition of Spark Therapeutics. 17 December 2019
Cancer-focused Chinese biotech BeiGene today announced results from the Phase III ASPEN trial comparing its BTK inhibitor Brukinsa (zanubrutinib) to ibrutinib for the treatment of Waldenström’s macroglobulinemia (WM). 16 December 2019
Roche’s long-delayed $4.3 billion acquisition of Spark Therapeutics, announced in February, moved a step forward to completion, with the news that it has been cleared by the UK’s regulator, though in the USA approval is still awaited,
. 16 December 2019
A US jury has ordered the Gilead Sciences subsidiary Kite Pharma to pay a total of $752 million to Juno Therapeutics – which has now become part of Bristol-Myers Squibb – and the Memorial Sloan Kettering Cancer Center (MSKCC). 16 December 2019
There are currently no approved treatments for the increasingly prevalent liver disease non-alcoholic steatohepatitis (NASH), but this looks highly likely to change within the next year. 16 December 2019
Rare and rheumatic disease specialist Horizon Therapeutics has been boosted by a unanimous vote from a key FDA advisory panel in favor of its ophthalmic candidate teprotumumab. 16 December 2019
US biotech major Biogen today announced disappointing top-line results from the Phase II PASSPORT study of gosuranemab (BIIB092) for progressive supranuclear palsy (PSP). 13 December 2019
French oncology-focused biotech company Innate Pharma was down more than 5% during Friday afternoon’s trading after the firm provided an update on its TELLOMAK Phase II trial on lacutamab. 13 December 2019
The US Food and Drug Administration has granted accelerated approval for its Vyondys 53 (golodirsen) injection to treat Duchenne muscular dystrophy (DMD) patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. 13 December 2019
French cancer immunotherapies biotech Transgene announced after European markets closed on Thursday that the primary endpoint (overall response rate) of the Phase II trial evaluating its TG4010 in combination with chemotherapy and Opdivo (nivolumab) was not reached. 13 December 2019
Switzerland-based biotech Numab have formed a partnership focusing on the development and commercialization of a portfolio of novel multi-specific antibodies for the therapy of cancer based on Numab’s technology platform with 3Sbio subsidiary Sunshine Guojian Pharmaceutical. 12 December 2019
Danish dermatology specialist LEO Pharma says that tralokinumab – an investigational, fully-human monoclonal antibody that specifically neutralizes the interleukin-13 (IL-13) cytokine – met all primary and secondary endpoints in its three pivotal Phase III studies (ECZTRA 1-3) for the treatment of moderate-to-severe atopic dermatitis (AD) in adults. During the studies, the overall adverse event rate was comparable between tralokinumab and placebo. 12 December 2019
French start-up GoLiver Therapeutics has signed an agreement with Paul-Brousse Hospital, a specialist center for hepatobiliary diseases in Paris that has already conducted clinical trials of innovative therapies for the liver. 12 December 2019